Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages

  Ziros, Panos G ^a   Manolakou, Stavroula D ^a,b   Habeos, Ioannis G ^a   Lilis, Ioannis ^a   Chartoumpekis, Dionysios V ^a   Koika, Vasiliki ^a   Soares, Paula ^c   Kyriazopoulou, Venetsana E ^a   Scopa, Chrisoula D ^a   Papachristou, Dionysios J ^a,d   Sykiotis, Gerasimos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; NQO1 PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAF GENE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KEAP1 GENE; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; NFE2L2 GENE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; THYROID ADENOMA; THYROID CARCINOMA; THYROID HYPERPLASIA; TRANSCRIPTION REGULATION;

ALDEHYDES; ANTIOXIDANTS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84881507544     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1510     Document Type: Article

References (21)

1. Maier J, van Steeg H, van Oostrom C, Paschke R, Weiss RE, Krohn K. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim Biophys Acta. 2007;1773:990-999.
2. Poncin S, Colin IM, Gerard AC. Minimal oxidative load: a prerequisite for thyroid cell function. J Endocrinol. 2009;201:161-167.
3. Poncin S, Van Eeckoudt S, Humblet K, Colin IM, Gerard AC. Oxidative stress: a required condition for thyroid cell proliferation. Am J Pathol. 2010;176:1355-1363.
4. Leoni SG, Kimura ET, Santisteban P, De la Vieja A. Regulation of thyroid oxidative state by thioredoxin reductase has a crucial role in thyroid responses to iodide excess. Mol Endocrinol. 2011;25:1924-1935.
5. Lee JM, Li J, Johnson DA, et al. Nrf2, a multi-organ protector? FASEB J. 2005;19:1061-1066.
6. Sykiotis GP, Bohmann D. 2010 Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal. 2010;3:re3.
7. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3:e420.
8. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations inNRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 2008;105:13568-13573.
9. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun. 2008;373:151-154.
10. DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotesROSdetoxification and tumorigenesis. Nature. 2011;475:106-109.
11. Loignon M, Miao W, Hu L, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Cancer Ther. 2009;8: 2432-2440.
12. Du ZX, Yan Y, Zhang HY, et al. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells. J Clin Endocrinol Metab. 2011;96:E763-E771.
13. Zong ZH, Du ZX, Li N, et al. Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells. Biochim Biophys Acta. 2012;1823:1395-1404.
14. DeLellis RA. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press; 2004.
15. Papachristou DJ, Sklirou E, Corradi D, Grassani C, Kontogeorgakos V, Rao UN. Immunohistochemical analysis of the endoribonucleases Drosha, Dicer and Ago2 in smooth muscle tumours of soft tissues. Histopathology. 2012;60:E28-E36.
16. Challeton C, Branea F, Schlumberger M, et al. Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int J Radiat Oncol Biol Phys. 1997; 37:163-169.
17. Tanaka J, Ogura T, Sato H, Hatano M. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology. 1987;161:62-72.
18. Cone RD, Platzer M, Piccinini LA, Jaramillo M, Davies TF. HLA-DRgene expression in a proliferating human thyroid cell clone (12S). Endocrinology. 1988;123:2067-2074.
19. Ralser M, Querfurth R, Warnatz HJ, Lehrach H, Yaspo ML, Krobitsch S. An efficient and economic enhancer mix for PCR. Biochem Biophys Res Commun. 2006;347:747-751.
20. Myers MB, McKim KL, Parsons BL. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid [published online ahead of print August 28, 2012]. Mol Carcinog. doi:10.1002/mc.21953.
21. Young O, Crotty T, O'Connell R, O'Sullivan J, Curran AJ. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck. 2010;32:750-756.